Eisai delays Eritoran application; Shire touts rival to Genzyme's Gaucher's drug;

 @FierceBiotech: Genentech looking to hire smart, creative types. Report | Follow @FierceBiotech

 @JohnCFierce: Glad to see reform story can fade now. For a daily grunt like me, it seems to be sucking all the air out of the biotech newsroom. | Follow @JohnCFierce

> Eisai announced today that it's delaying its application for the sepsis drug Eritoran. Eisai release

> Alnylam CEO John Maraganore discusses his company's clinical programs, partnering potential and cash position in an interview with Reuters. Story

> Shire is reporting data the company says proves it's safe for patients to switch to the company's newly-approved drug to treat Gaucher's disease, from a better-known rival produced by Genzyme. Report

> GlaxoSmithKline exercised its option to buy 1.56 million common shares of JCR Pharmaceuticals. Report

And Finally... Scientists have found a new and simple way to identify breast cancer patients who are likely to respond well to treatment with a common class of chemotherapy drugs. Report

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.